Please use this identifier to cite or link to this item:
Title: Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
Austin Authors: Lim, Yen Ying;Maruff, Paul;Pietrzak, Robert H;Ellis, Kathryn A;Darby, David G;Ames, David;Harrington, Karra;Martins, Ralph N;Masters, Colin L ;Szoeke, Cassandra;Savage, Greg;Villemagne, Victor L ;Rowe, Christopher C 
Institutional Author: AIBL Research Group
Affiliation: CogState Ltd., Melbourne, Victoria, Australia
National Ageing Research Institute, Parkville, Victoria, Australia
Department of Psychology and ARC Centre of Excellence in Cognition and Its Disorders, Macquarie University, Sydney, New South Wales, Australia
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Kew, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
CSIRO Preventative Health Flagship, Parkville, Victoria, Australia
Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical, and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
Issue Date: 28-Feb-2014
Publication information: Alzheimer's & Dementia : the Journal of the Alzheimer's Association 2014; 10(6): 743-751.e1
Abstract: High β-amyloid (Aβ) is associated with faster memory decline in healthy individuals and adults with mild cognitive impairment (MCI). However, longer prospective studies are required to determine if Aβ-related memory decline continues and whether it is associated with increased rate of disease progression.Healthy controls (HCs; n = 177) and adults with MCI (n = 48) underwent neuroimaging for Aβ and cognitive assessment at baseline. Cognition was reassessed 18 and 36 months later.Compared with low-Aβ HCs, high-Aβ HC and MCI groups showed moderate decline in episodic and working memory over 36 months. Those with MCI with low Aβ did not show any cognitive decline. Rates of disease progression were increased in the high-Aβ HC and MCI groups.In healthy individuals, high Aβ likely indicates that Alzheimer's disease (AD)-related neurodegeneration has begun. Once commenced, the rate of decline in cognitive function remains constant across the preclinical and prodromal stages of AD.
DOI: 10.1016/j.jalz.2013.11.005
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Type: Journal Article
Cognitive decline
Preclinical AD
Prodromal AD
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.